Current Environment: Production

Recall Alert

There is an antibacterial antibiotic recall. Read more →
617-632-5508
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Location Page
/centers/cancer-and-blood-disorders-center

Education

Medical School

University of California, San Diego School of Medicine

1985, San Diego, CA

Internship

Boston Children's Hospital

1986, Boston, MA

Residency

Boston Children's Hospital

1988, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

1991, Boston, MA

Publications

  1. Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2025 Jun; 19(3):1112. View Abstract

  2. Pediatric Cancer Predisposition and Surveillance Update: Summary Perspective and Future Directions. Clin Cancer Res. 2025 May 06. View Abstract

  3. Accelerated Aging in Survivors of Childhood Cancer-Early Onset and Excess Risk of Chronic Conditions. JAMA Oncol. 2025 May 01; 11(5):535-543. View Abstract

  4. Data-driven consideration of genetic disorders for global genomic newborn screening programs. Genet Med. 2025 Apr 25; 101443. View Abstract

  5. Update on Surveillance in Von Hippel-Lindau Disease. Clin Cancer Res. 2025 Apr 15. View Abstract

  6. Response to Kratz, Plon, and Lupo. J Natl Cancer Inst. 2025 Apr 01; 117(4):814-815. View Abstract

  7. Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers. J Natl Cancer Inst. 2025 Apr 01; 117(4):728-736. View Abstract

  8. Update on Surveillance Guidelines in Emerging Wilms Tumor Predisposition Syndromes. Clin Cancer Res. 2025 Jan 06; 31(1):18-24. View Abstract

  9. Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith-Wiedemann Syndrome and Other Predisposition Syndromes. Clin Cancer Res. 2024 Dec 02; 30(23):5260-5269. View Abstract

  10. Neuroblastoma Predisposition and Surveillance-An Update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024 Aug 01; 30(15):3137-3143. View Abstract

  11. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiother Oncol. 2024 09; 198:110384. View Abstract

  12. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2024 Jun 07; 116(6):885-894. View Abstract

  13. The Association of Race, Ethnicity, and Insurance Status with the Visual Acuity of Retinoblastoma Survivors in the IRIS® Registry. Ophthalmic Epidemiol. 2025 Feb; 32(1):18-24. View Abstract

  14. Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 02; 18(1):34-41. View Abstract

  15. A nursing perspective on inpatient sleep and circadian disruptions for pediatric stem cell transplant patients. Pediatr Blood Cancer. 2024 Mar; 71(3):e30816. View Abstract

  16. Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111. View Abstract

  17. Assisted reproductive technology use and outcomes in childhood cancer survivors. Cancer. 2024 01 01; 130(1):128-139. View Abstract

  18. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 08; 70(8):e30418. View Abstract

  19. Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. 2023 09 15; 129(18):2904-2914. View Abstract

  20. Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort. Lancet Oncol. 2023 06; 24(6):691-700. View Abstract

  21. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576. View Abstract

  22. Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study (CCSS). JAMA Oncol. 2022 Oct 13. View Abstract

  23. Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer Prev Res (Phila). 2022 10 04; 15(10):645-652. View Abstract

  24. Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1675-1682. View Abstract

  25. Predicting chronic morbidity in childhood cancer survivors. Nat Med. 2022 08; 28(8):1539-1540. View Abstract

  26. Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clin Cancer Res. 2022 06 13; 28(12):2579-2586. View Abstract

  27. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. J Clin Oncol. 2022 09 10; 40(26):3047-3056. View Abstract

  28. Advanced Retinoblastoma Presenting with Cataract in a Child with Limited Access to Primary Care. J Pediatr. 2022 08; 247:171-172. View Abstract

  29. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. J Natl Cancer Inst. 2022 05 09; 114(5):722-731. View Abstract

  30. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. J Natl Cancer Inst. 2022 02 07; 114(2):235-244. View Abstract

  31. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 10 01; 4(10):e2129742. View Abstract

  32. Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy. Pediatr Blood Cancer. 2021 10; 68(10):e29127. View Abstract

  33. Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genet Med. 2021 07; 23(7):1366-1371. View Abstract

  34. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2021 07 10; 39(20):2266-2275. View Abstract

  35. Timely pediatric cancer diagnoses: An unexpected casualty of the COVID-19 surge. Pediatr Blood Cancer. 2020 12; 67(12):e28729. View Abstract

  36. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2020 11 20; 38(33):3851-3862. View Abstract

  37. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. Ann Intern Med. 2020 09 01; 173(5):331-341. View Abstract

  38. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View Abstract

  39. Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Eur J Cancer. 2020 07; 133:4-13. View Abstract

  40. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. View Abstract

  41. Linking population-based registries to identify familial cancer risk in childhood cancer. Cancer. 2020 07 01; 126(13):3076-3083. View Abstract

  42. Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol. 2020 03 01; 6(3):350-357. View Abstract

  43. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. View Abstract

  44. Autonomous early detection of eye disease in childhood photographs. Sci Adv. 2019 10; 5(10):eaax6363. View Abstract

  45. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. View Abstract

  46. Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2019 10; 20(10):1420-1431. View Abstract

  47. Late-onset anorectal disease and psychosocial impact in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2019 11 01; 125(21):3873-3881. View Abstract

  48. Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study. J Clin Oncol. 2019 08 20; 37(24):2131-2140. View Abstract

  49. Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2019 08 20; 37(24):2120-2130. View Abstract

  50. Cancer Treatment-Related Infertility: A Critical Review of the Evidence. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz008. View Abstract

  51. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. View Abstract

  52. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Cancer. 2019 04 15; 125(8):1373-1383. View Abstract

  53. Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018 Sep 14; JCO2018784595. View Abstract

  54. Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2018 08; 124(16):3436-3444. View Abstract

  55. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. 2018 08 01; 124(15):3220-3230. View Abstract

  56. Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018 06 01; 36(16):1571-1578. View Abstract

  57. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018 01 10; 20(1):132-142. View Abstract

  58. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View Abstract

  59. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 07 01; 23(13):e98-e106. View Abstract

  60. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clin Cancer Res. 2017 Jun 15; 23(12):e62-e67. View Abstract

  61. PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e76-e82. View Abstract

  62. Understanding predictors of continued long-term pediatric cancer care across the region: A report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2017 Oct; 64(10). View Abstract

  63. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1327-1334. View Abstract

  64. Neuroblastoma. Nat Rev Dis Primers. 2016 11 10; 2:16078. View Abstract

  65. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View Abstract

  66. Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. Pediatr Blood Cancer. 2017 02; 64(2):346-352. View Abstract

  67. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract

  68. Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. J Natl Cancer Inst. 2016 09; 108(9). View Abstract

  69. Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016 Mar 20; 34(9):910-8. View Abstract

  70. Health care utilization, lifestyle, and emotional factors and mammography practices in the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1699-706. View Abstract

  71. Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2015 Sep 10; 33(26):2893-900. View Abstract

  72. An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome? Pediatr Blood Cancer. 2016 Feb; 63(2):196-201. View Abstract

  73. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. View Abstract

  74. Childhood Cancer Survivor Study participants' perceptions and understanding of the Affordable Care Act. J Clin Oncol. 2015 Mar 01; 33(7):764-72. View Abstract

  75. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. View Abstract

  76. Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. 2015 Jan 15; 121(2):286-93. View Abstract

  77. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer. 2014 Aug 15; 120(16):2507-13. View Abstract

  78. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med. 2014 May 20; 160(10):661-71. View Abstract

  79. Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2014 Aug 15; 120(16):2514-21. View Abstract

  80. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014 Jul 20; 32(21):2217-23. View Abstract

  81. Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. J Pediatr Hematol Oncol. 2014 Apr; 36(3):237-40. View Abstract

  82. Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation. Leuk Lymphoma. 2014 Nov; 55(11):2477-83. View Abstract

  83. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9. View Abstract

  84. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014 Apr; 49(4):502-8. View Abstract

  85. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014 Apr 01; 120(7):1068-75. View Abstract

  86. Partnership for health-2, a web-based versus print smoking cessation intervention for childhood and young adult cancer survivors: randomized comparative effectiveness study. J Med Internet Res. 2013 Nov 05; 15(11):e218. View Abstract

  87. Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014 Feb; 61(2):319-25. View Abstract

  88. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014 Jan; 61(1):53-67. View Abstract

  89. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. View Abstract

  90. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013 Aug; 14(9):873-81. View Abstract

  91. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013 Jun 20; 31(18):2282-8. View Abstract

  92. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52. View Abstract

  93. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80. View Abstract

  94. Influence of new late effects on quality of life over time in Hodgkin lymphoma Survivors: a longitudinal survey study. Ann Oncol. 2013 Jan; 24(1):226-30. View Abstract

  95. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks. Blood. 2012 Sep 13; 120(11):2195-202. View Abstract

  96. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):224-30. View Abstract

  97. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Nov; 59(5):902-7. View Abstract

  98. New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. J Clin Oncol. 2012 Jun 20; 30(18_suppl):CRA9513. View Abstract

  99. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med. 2012 Jun 05; 156(11):757-66, W-260. View Abstract

  100. Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. Ann Intern Med. 2012 Jun 05; 156(11):I-36. View Abstract

  101. Childhood Cancer Survivor Study participants' perceptions and knowledge of health insurance coverage: implications for the Affordable Care Act. J Cancer Surviv. 2012 Sep; 6(3):251-9. View Abstract

  102. Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study. Leuk Lymphoma. 2012 Aug; 53(8):1474-80. View Abstract

  103. Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):506-10. View Abstract

  104. How confident are young adult cancer survivors in managing their survivorship care? A report from the LIVESTRONG™ Survivorship Center of Excellence Network. J Cancer Surviv. 2011 Dec; 5(4):371-81. View Abstract

  105. Clinical practice. Adult primary care after childhood acute lymphoblastic leukemia. N Engl J Med. 2011 Oct 13; 365(15):1417-24. View Abstract

  106. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011 Aug 04; 118(5):1413-20. View Abstract

  107. Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide equivalent dose-A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2011 May 20; 29(15_suppl):9547. View Abstract

  108. Disseminating a smoking cessation intervention to childhood and young adult cancer survivors: baseline characteristics and study design of the partnership for health-2 study. BMC Cancer. 2011 May 11; 11:165. View Abstract

  109. Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology. 2011 May; 140(5):1464-71.e1. View Abstract

  110. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011 Mar 04; 108(5):619-28. View Abstract

  111. The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1062-6. View Abstract

  112. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010 Dec 20; 28(36):5327-47. View Abstract

  113. Breastfeeding in survivors of Hodgkin lymphoma treated with chest radiotherapy. Cancer. 2010 Oct 15; 116(20):4866-71. View Abstract

  114. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38. View Abstract

  115. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010 Aug 20; 28(24):3808-15. View Abstract

  116. Decision analysis to compare treatment strategies for Stage I/favorable histology Wilms tumor. Pediatr Blood Cancer. 2010 Jul 01; 54(7):879-84. View Abstract

  117. Pharmacotherapy of neuroblastoma. Expert Opin Pharmacother. 2010 Jun; 11(9):1467-78. View Abstract

  118. Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study. Cancer Causes Control. 2010 Oct; 21(10):1585-95. View Abstract

  119. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010 Apr 06; 152(7):409-17, W131-8. View Abstract

  120. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010 Apr 06; 152(7):444-55; W144-54. View Abstract

  121. Health status of the oldest adult survivors of cancer during childhood. Cancer. 2010 Jan 15; 116(2):497-505. View Abstract

  122. Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists. J Clin Oncol. 2010 Feb 10; 28(5):878-83. View Abstract

  123. Ovarian tissue autologous transplantation to the upper extremity for girls receiving abdominal/pelvic radiation: 20-year follow-up of reproductive endocrine function. J Pediatr Adolesc Gynecol. 2010 Apr; 23(2):107-10. View Abstract

  124. General internist communication about sexual function with cancer survivors. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S407-11. View Abstract

  125. Suicide ideation in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010 Feb 01; 28(4):655-61. View Abstract

  126. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009 Sep 15; 115(18 Suppl):4409-18. View Abstract

  127. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009 Aug 19; 101(16):1131-40. View Abstract

  128. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009 Aug 20; 27(24):3901-7. View Abstract

  129. Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol. 2009 May 20; 27(15_suppl):6561. View Abstract

  130. Cancer care and cancer survivorship care in the United States: will we be able to care for these patients in the future? J Oncol Pract. 2009 May; 5(3):119-23. View Abstract

  131. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009 May 10; 27(14):2339-55. View Abstract

  132. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009 Jan 28; 301(4):404-14. View Abstract

  133. The LIVESTRONG Survivorship Center of Excellence Network. J Cancer Surviv. 2009 Mar; 3(1):4-11. View Abstract

  134. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26. View Abstract

  135. Long-term smoking cessation outcomes among childhood cancer survivors in the Partnership for Health Study. J Clin Oncol. 2009 Jan 01; 27(1):52-60. View Abstract

  136. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008 Nov; 51(5):589-92. View Abstract

  137. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8. View Abstract

  138. New primary sarcomas in survivors of childhood cancer: A detailed analysis of the effects of treatment: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008 May 20; 26(15_suppl):10007. View Abstract

  139. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9. View Abstract

  140. Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatr Blood Cancer. 2008 Feb; 50(2):246-9. View Abstract

  141. Health practice in long-term survivors of Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):468-76. View Abstract

  142. Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ovarian function. Hum Reprod. 2008 Jan; 23(1):117-21. View Abstract

  143. Screening adult survivors of childhood cancer with the distress thermometer: a comparison with the SCL-90-R. Psychooncology. 2007 Nov; 16(11):1046-9. View Abstract

  144. The effects of response bias on self-reported quality of life among childhood cancer survivors. Qual Life Res. 2007 Sep; 16(7):1211-20. View Abstract

  145. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255. View Abstract

  146. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007 Feb 21; 99(4):300-8. View Abstract

  147. Perceptions of breast cancer risk and cancer screening: a qualitative study of young, female Hodgkin's disease survivors. J Cancer Educ. 2007; 22(1):42-6. View Abstract

  148. Transitioning to survivorship: a pilot study. J Pediatr Oncol Nurs. 2006 Nov-Dec; 23(6):335-43. View Abstract

  149. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006 Oct 01; 12(19):5693-7. View Abstract

  150. A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma. Pediatr Transplant. 2006 Sep; 10(6):669-76. View Abstract

  151. Suicidal ideation and attempts in adult survivors of childhood cancer. J Clin Oncol. 2006 Aug 20; 24(24):3852-7. View Abstract

  152. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6. View Abstract

  153. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol. 2005 Dec; 16(12):1949-55. View Abstract

  154. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20; 23(27):6466-73. View Abstract

  155. Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma. Paediatr Anaesth. 2005 Jul; 15(7):606-10. View Abstract

  156. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg. 2005 Jun; 40(6):936-41; discussion 941. View Abstract

  157. Neuropsychological resiliency after treatment for advanced stage neuroblastoma. Bone Marrow Transplant. 2005 Jun; 35(11):1117-22. View Abstract

  158. CT-guided radiofrequency ablation of pediatric Wilms tumor in a solitary kidney. Pediatr Radiol. 2005 Sep; 35(9):923-8. View Abstract

  159. Sarcomas as a subsequent malignancy in survivors of pediatric malignancy:The Childhood Cancer Survivor Study. J Clin Oncol. 2005 Jun; 23(16_suppl):8515. View Abstract

  160. A phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol. 2005 Jun; 23(16_suppl):8530. View Abstract

  161. Second cancers screening in pediatric cancer survivors: A single institution study. J Clin Oncol. 2005 Jun; 23(16_suppl):8538. View Abstract

  162. Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens. 2005 Jan; 19(1):33-45. View Abstract

  163. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 2004 Oct 19; 141(8):590-7. View Abstract

  164. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004 Aug 01; 22(15):3139-48. View Abstract

  165. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. Journal of Clinical Oncology. 2004; 22(15):3139-3148.

  166. Recurrent neuroblastoma: Randomized treatment with topotecan + cyclophosphamide (T+C) vs. topotecan alone(T). A POG/CCG Intergroup Study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8512. View Abstract

  167. A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8551. View Abstract

  168. Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr. 2004 Apr; 144(4):444-8. View Abstract

  169. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness. Cancer Res. 2004 Feb 01; 64(3):928-33. View Abstract

  170. A feasibility study of tamoxifen chemotherapy prevention in Hodgkin’s disease (HD) survivors. Long-Term Complications of Treatment of Children and Adolescents for Cancer. 2004; (Ontario).

  171. Transitioning to survivorship: a pilot study. Long-Term Complications of Treatment of Children and Adolescents for Cancer. 2004; (Ontario).

  172. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. J Clin Oncol. 2003 Dec 15; 21(24):4505-9. View Abstract

  173. The TP53, BRCA1 and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin’s disease with second primary neoplasms. Journal of Clinical Oncology. 2003; 21(24):4505-9.

  174. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol. 2003 Dec 01; 158(11):1108-13. View Abstract

  175. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003 Dec 01; 21(23):4386-94. View Abstract

  176. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol. 2003 Dec; 25(12):934-40. View Abstract

  177. Utility of routine psychological screening in the childhood cancer survivor clinic. J Clin Oncol. 2003 Mar 01; 21(5):787-92. View Abstract

  178. Utility of routine psychological screening in the childhood cancer survivor clinic. Journal of Clinical Oncology. 2003; 21(5):787-92.

  179. Angiogenesis inhibitor TNP-470 during bone marrow transplant and in minimal residual disease. Transplantation in Hematology and Oncology II, Berdel WE, et al, eds. 2003; 283-298.

  180. Rapid Sequence Tandem Transplant in Children with High-Risk Neruroblastoma. Transplantation in Hematology and Oncology II, Berdel WE, et al, eds. 2003; 270-279.

  181. Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genetics and Cytogenetics. 2003; 141(2):97-105.

  182. Primary tumor control in patients with stage 3 and 4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. Journal of Pediatric Hematology/Oncology. 2003; 25(12):934-40.

  183. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin disease: report from the Late Effects Study Group (LESG). Journal of Clinical Oncology. 2003; 21(23):4386-94.

  184. Successful purging of stem cell products using CD34 selection. Transplantation in Hematology and Oncology II, Berdel WE, et al, eds. 2003; 116-129.

  185. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002 Apr 15; 20(8):2085-91. View Abstract

  186. Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol. 2002 Mar 15; 20(6):1608-16. View Abstract

  187. MYCN copy number and hyperdiploidy: do they define a favourable prognostic group in neuroblastoma patients between 12 and 24 months of age? A COG study. Advances in Neuroblastoma Research. 2002; (Paris ).

  188. Neuropsychological and psychosocial resiliency in children treated for neuroblastoma. Advances in Neuroblastoma Research. 2002; (Paris).

  189. Breast cancer screening in women previously treated for Hodgkin’s disease: A prospective cohort study. Journal of Clinical Oncology. 2002; 20(8):2085-2091.

  190. Predictors of Smoking Initiation and Cessation Among Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology. 2002; 20(6):1608-1616.

  191. Rapid sequence tandem transplant for advanced neuroblastoma: update and patterns of relapse. Advances in Neuroblastoma Research. 2002; (Paris).

  192. RB1 genetic testing as a clinical service: a follow-up study. Med Pediatr Oncol. 2001 Oct; 37(4):372-8. View Abstract

  193. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene. 2001 Jul 27; 20(33):4441-9. View Abstract

  194. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res. 2001 Apr; 7(4):1026-32. View Abstract

  195. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001 Feb 01; 91(3):613-21. View Abstract

  196. Angiogenesis inhibitor TNP-470 during bone marrow transplant: Safety in a preclinical model. Clinical Cancer Research. 2001; 7:1026-32.

  197. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol. 2000 Dec; 35(6):677-82. View Abstract

  198. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):696-700. View Abstract

  199. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000 Jul; 18(13):2567-75. View Abstract

  200. Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2000 May; 18(10):2026-31. View Abstract

  201. Measurement of problem-solving deficits in adults with acquired brain damage. J Head Trauma Rehabil. 2000 Feb; 15(1):724-33. View Abstract

  202. ADHD, divorce, and parental disagreement about the diagnosis and treatment. J Dev Behav Pediatr. 2000 Feb; 21(1):53-5. View Abstract

  203. Center surround receptive field structure of cone bipolar cells in primate retina. Vision Res. 2000; 40(14):1801-11. View Abstract

  204. Characteristics and outcome of children with Beckwith-Weidemann syndrome and Wilms tumor: a report from the National Wilms Tumor Study Group. Journal of Clinical Oncology. 2000; 18:2026-31.

  205. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. Journal of Clinical Oncology. 2000; 18(13):2567-75.

  206. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999 Apr; 17(4):1259. View Abstract

  207. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin’s disease. Journal of Clinical Oncology. 1999; 4:1259-66.

  208. Constitutional WT1 mutations in Wilms' tumor patients. J Clin Oncol. 1998 Nov; 16(11):3634-40. View Abstract

  209. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998 Oct; 22(7):669-74. View Abstract

  210. Childhood cancer predisposition: applications of molecular testing and future implications. J Pediatr. 1998 Mar; 132(3 Pt 1):389-97. View Abstract

  211. Cystic neuroblastoma: emphasis on gene expression, morphology, and pathogenesis. Pediatr Dev Pathol. 1998 Jan-Feb; 1(1):17-28. View Abstract

  212. Constitutional WT1 mutations in Wilms tumor patients. Journal of Clinical Oncology. 1998; 11:3634-40.

  213. Cystic neuroblastoma: emphasis on gene expression, morphology, and pathogenesis. Pediatric and Developmental Pathology. 1998; 1:17-28.

  214. The case of the missing methylphenidate. Pediatrics. 1997 Oct; 100(4):730-1. View Abstract

  215. Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med. 1997 Sep; 42(9):537-41. View Abstract

  216. Epidemiology of cancer in childhood.Eds. Nathan DG, Orkin SH. In: Nathan and Oski’s Hematology of Infancy and Childhood. 1997; 1071-91.

  217. Use of growth hormone for non-growth hormone deficient children. JAMA. 1996 Dec 18; 276(23):1877-8; author reply 1878. View Abstract

  218. Germline WT1 mutations in Wilms' tumor patients: preliminary results. Med Pediatr Oncol. 1996 Nov; 27(5):404-7. View Abstract

  219. Percutaneous biopsy for prognostic testing of neuroblastoma. Radiology. 1996 Jul; 200(1):213-6. View Abstract

  220. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis. 1996 Jan; 173(1):256-8. View Abstract

  221. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer. J Clin Apher. 1996; 11(4):195-203. View Abstract

  222. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin’s disease. Journal of Infectious Diseases. 1996; 173(1):256-8.

  223. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med. 1995 Dec 01; 123(11):828-34. View Abstract

  224. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995 Apr; 95(4):1606-11. View Abstract

  225. A new technique for laparoscopic prophylactic oophoropexy prior to cranial irradiation in children with medulloblastoma. Adolescent and Pediatric Gynecology. 1995; 8:77-81.

  226. Preferential amplification of the paternal allele in neuroblastomas with n-myc amplification. In: Advances in Neuroblastoma Research. 1994; 39-43.

  227. Overview of Familial Cancers. Genetic Resource. 1994; 8:12-19.

  228. Preferential amplification of the paternal allele in neuroblastomas with N-myc amplification. Prog Clin Biol Res. 1994; 385:43-9. View Abstract

  229. Screening children at genetic risk of cancer. Curr Opin Pediatr. 1993 Dec; 5(6):712-5. View Abstract

  230. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics. 1993 Sep; 92(3):358-64. View Abstract

  231. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet. 1993 Jun; 4(2):191-4. View Abstract

  232. Cognitive remediation in traumatic brain injury: update and issues. Arch Phys Med Rehabil. 1993 Feb; 74(2):204-13. View Abstract

  233. Stress, appraisal, and coping in mothers of disabled and nondisabled children. J Pediatr Psychol. 1992 Oct; 17(5):587-605. View Abstract

  234. Structure and expression of the Xenopus retinoblastoma gene. Dev Biol. 1992 Sep; 153(1):141-9. View Abstract

  235. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol. 1992 Aug; 4(4):689-95. View Abstract

  236. Identification of cancer-prone individuals: p53 and family cancer syndromes. J Natl Cancer Inst Monogr. 1992; (12):123-4. View Abstract

  237. Cancer Survivor Initiative Project (National Cancer Institute Contract MAO NCICC)-84332 (PI:Patenaude). Curriculum for health care providers working with young adult survivors. Co-author of medical information summaries section of curriculum. 1992.

  238. Neuroblastoma. The Fetus. 1991; 1:1-4.

  239. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 1990 Nov; 10(11):5772-81. View Abstract

  240. Parameters of emotional processing in neuropsychiatric disorders: conceptual issues and a battery of tests. J Commun Disord. 1990 Aug-Oct; 23(4-5):247-71. View Abstract

  241. First year after stroke: tracking cognitive and affective deficits. Arch Phys Med Rehabil. 1989 Apr; 70(4):297-302. View Abstract

  242. Unilateral spatial neglect: biases in contralateral search and fine spatial attention. Arch Clin Neuropsychol. 1988; 3(3):213-25. View Abstract

  243. Proper and common nouns: form class judgments in Broca's aphasia. Brain Lang. 1986 May; 28(1):114-25. View Abstract

  244. Psychosocial aspects of living with cancer: a review of the literature. Int J Psychiatry Med. 1981-1982; 11(4):303-29. View Abstract

  245. Assessment and treatment of psychosocial problems of the cancer patient: a case study. Cancer Nurs. 1980 Apr; 3(2):111-9. View Abstract

  246. Male contraception and family planning: a social and historical review. Fertil Steril. 1977 Dec; 28(12):1271-9. View Abstract

  247. Rehabilitation performance and adjustment in stroke patients: a study of social class factors. Genet Psychol Monogr. 1976 May; 93(2):287-352. View Abstract

  248. The effect of hyperbaric oxygen on communication function in adults with aphasia secondary to stroke. J Speech Hear Res. 1972 Mar; 15(1):42-8. View Abstract

  249. The effect of hyperbaric oxygen on the mental and verbal ability of stroke patients. Stroke. 1972 Jan-Feb; 3(1):10-5. View Abstract

  250. Music as a facilitator for visual motor sequencing tasks in children with cerebral palsy. Dev Med Child Neurol. 1971 Jun; 13(3):335-42. View Abstract

  251. Perceptual and intellectual problems in hemiplegia: implications for rehabilitation. Med Clin North Am. 1969 May; 53(3):575-83. View Abstract

  252. The relationship between impersistence, intellectual function and outcome of rehabilitation in patients with left hemiplegia. Neurology. 1968 Sep; 18(9):852-61. View Abstract

  253. The effects of oxygen inhalation on motor impersistence in brain-damaged individuals: a double-blind study. Neurology. 1967 Oct; 17(10):1003-10. View Abstract

  254. Follow-up study of the results of anterior choroidal artery occlusion and subtemporal chemopallidectomy in parkinson's disease: an independent appraisal. J Am Geriatr Soc. 1956 Dec; 4(12):1249-57. View Abstract

Education

Medical School

University of California, Los Angeles School of Medicine

1986, Los Angeles, CA

Internship

Boston Children's Hospital

1987, Boston, MA

Residency

Boston Children's Hospital

1989, Boston, MA

Fellowship

Boston Children's Hospital / Dana Farber Cancer Institute

1992, Boston, MA

Publications

Education

Medical School

University of Virginia School of Medicine

1991, Charlottesville, VA

Internship

General Surgery

Georgetown University Hospital

Washington, DC

Residency

Surgery

Georgetown University Hospital

Washington, DC

Residency

Radiation Oncology

University of Pennsylvania School of Medicine

1995, Philadelphia, PA

Fellowship

Brachytherapy

Memorial Sloan Kettering Cancer Center

1996, New York, NY

Publications

Education

Undergraduate School

Boston University

1999, Boston, MA

Medical School

Boston University School of Medicine

2003, Boston, MA

Residency

Pediatrics

University of California, San Francisco Medical Center

2006, San Francisco, CA

Fellowship

Boston Children's Hospital/Dana-Farber Cancer Institute

Pediatric Hematology-Oncology Program

Boston, MA

Publications

Education

Undergraduate School

Cornell University

Ithaca, NY

Graduate School

PhD

Washington University School of Medicine

St. Louis, MO

Medical School

Washington University School of Medicine

St. Louis, MO

Internship

St. Louis Children's Hospital

St. Louis, MO

Residency

St. Louis Children's Hospital

St. Louis, MO

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

Boston, MA

Publications

Education

Medical School

University of Virginia School of Medicine

2009, Charlottesville, VA

Internship

Boston Combined Residency Program (BCRP)

2010, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2011, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders

2015, Boston, MA

Publications

Education

Medical School

Ludwig-Maximilians-Universitaet

Munich, Germany

Residency

University of Washington / Seattle Children's Hospital

Seattle, WA

Fellowship

Boston Children's Hospital / Dana Farber Cancer Institute

Boston, MA

Publications

Education

Medical School

Monash University Medical School

Melbourne, Australia

Residency

Pediatrics

Royal Children's Hospital

2005, Melbourne, Australia

Fellowship

Pediatric Hematology-Oncology

Royal Children's Hospital

2009, Melbourne, Australia

Fellowship

Pediatric Neuro-Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

2013, Boston, MA

Publications

Education

Medical School

New York Medical College

2009, Valhalla, NY

Internship

Boston Combined Residency Program (BCRP)

2010, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2012, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Dana Farber Cancer Institute/Boston Children’s Hospital

2015, Boston, MA

Publications

Education

Medical School

University of Pennsylvania

Philadelphia, PA

Internship

Boston Children's Hospital

Boston, MA

Residency

Pediatrics

Boston Children's Hospital

Boston, MA

Fellowship

Pediatric Hematology/Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

Boston, MA

Publications
Subscribe to Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

For questions regarding an appointment, doctor notes, or specific questions related to symptoms/diagnosis, please call the department of clinic directly.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services